Which generation of targeted drug therapy does Adagrasib belong to?

Adagrasib is a targeted drug and belongs to the third generation of targeted drugs. Targeted drug therapy is one of the major advances in the field of cancer treatment in recent years. It mainly works by targeting specific molecular targets in tumor cells and minimizing damage to normal cells. Targeted drugs can be divided into different generations according to different targets, and adagrasib is a typical representative of the third generation.

The first generation of targeted drugs are mainly early targeted therapeutic drugs, which usually act on epidermal growth factor receptor (EGFR), HER2 and other targets on tumor cells. The advent of these drugs has significantly improved outcomes for cancer patients, especially in the treatment of cancers such as non-small cell lung cancer. However, as tumor cells tend to develop drug resistance, the effectiveness of these drugs may gradually diminish over time.

The second generation of targeted drugs improves on the first generation, usually improving efficacy through stronger targeting and the ability to treat different mutation types. The emergence of these drugs has solved some of the drug resistance problems and improved the accuracy and effectiveness of treatment. But they also have some side effects and drug resistance issues, especially as tumor cells continue to evolve.
As a third-generation targeted drug, adagrasib has stronger targeting and higher selectivity, and mainly acts on cancers with KRAS G12C mutations. KRAS mutations have always been difficult to treat because mutant forms of the gene often exhibit activity that is difficult to suppress. By precisely targeting the KRAS G12C mutation, adagrasib can effectively inhibit the growth of tumor cells and overcome the limitations of second-generation drugs in the face of this mutation. Therefore, adagrasib has made an important breakthrough in the field of targeted therapy.
The third generation of targeted drugs, such as adagrasib, not only improves treatment specificity and reduces the impact on normal cells, but also makes breakthroughs in solving tumor drug resistance. Therefore, adagrasib is considered an important drug in the current treatment of KRAS mutation-related cancers (such as non-small cell lung cancer, colorectal cancer, etc.), and has demonstrated significant clinical efficacy. As research deepens, third-generation targeted drugs may further change the landscape of tumor treatment.
Reference: https://www.krazati.com/